These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18355209)

  • 1. Tongue hyperpigmentation resulting from peginterferon alpha-2a and ribavirin treatment in a Caucasian patient with chronic hepatitis C.
    Fernández A; Vázquez S; Rodríguez-González L
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1389-91. PubMed ID: 18355209
    [No Abstract]   [Full Text] [Related]  

  • 2. Tongue hyperpigmentation during hepatitis C treatment.
    Bachmeyer C; Pellen JC
    CMAJ; 2012 Sep; 184(13):1498. PubMed ID: 22451683
    [No Abstract]   [Full Text] [Related]  

  • 3. Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
    Mlika RB; Kerkeni N; Marrak H; Fenniche S; Mokhtar I; Debbiche A
    Int J Dermatol; 2013 May; 52(5):643-4. PubMed ID: 23046405
    [No Abstract]   [Full Text] [Related]  

  • 4. Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.
    Torres HA; Bull L; Arduino RC; Barnett BJ
    Am J Gastroenterol; 2007 Jun; 102(6):1334-5. PubMed ID: 17531028
    [No Abstract]   [Full Text] [Related]  

  • 5. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
    Howell CD; Jeffers LS; Cassidy W; Reddy KR; Hu S; Lee JS
    J Viral Hepat; 2006 Jun; 13(6):371-6. PubMed ID: 16842439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
    Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
    [No Abstract]   [Full Text] [Related]  

  • 7. [Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated].
    Márquez Peiró JF; Valero Alcocer VE; Morales Suárez-Varela M; Llopis González A; Pérez Peiró C
    Med Clin (Barc); 2007 Nov; 129(16):612-4. PubMed ID: 18001672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.
    Perrillo R; Rothstein KD; Rubin R; Alam I; Imperial J; Harb G; Hu S; Klaskala W
    J Viral Hepat; 2004 Mar; 11(2):157-65. PubMed ID: 14996351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.
    Gurguta C; Kauer C; Bergholz U; Formann E; Steindl-Munda P; Ferenci P
    Am J Gastroenterol; 2006 Jan; 101(1):197-8. PubMed ID: 16405555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.
    Ghosh S; Duseja A; Dhiman RK; Chawla YK
    Dig Dis Sci; 2012 Mar; 57(3):820-1. PubMed ID: 21948358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 15. Concurrent acute interstitial pneumonia and pulmonary embolism during treatment with peginterferon alpha-2a and ribavirin in a patient with hepatitis C.
    Coban H; Yahyaoglu M; Vatan MB
    Indian J Pharmacol; 2014; 46(4):443-5. PubMed ID: 25097288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C.
    Kwon JH; Bae SH; Choi JY; Yoon SK; Byun KS; Paik SW; Lim YS; Lee HC; Han KH; Lee KS
    Korean J Intern Med; 2009 Sep; 24(3):203-11. PubMed ID: 19721856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.